{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:26:41Z","timestamp":1768537601877,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,8,2]],"date-time":"2005-08-02T00:00:00Z","timestamp":1122940800000},"content-version":"vor","delay-in-days":1705,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:p><jats:bold>Summary: <\/jats:bold>  <jats:italic>Purpose<\/jats:italic>: The objective of this study was to evaluate the effect of a new antiseizure drug, retigabine (D\u201023129; <jats:italic>N<\/jats:italic>\u2010(2\u2010amino\u20104\u2010[fluorobenzylamino]\u2010phenyl) carbamic acid ethyl ester) on low\u2010Mg<jats:sup>2+<\/jats:sup>\u2010induced epileptiform discharges in rat in vitro.<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>: Three types of epileptiform discharges (recurrent short discharges in the hippocampus, seizure\u2010like events, and late recurrent discharges in the entorhinal cortex) were elicited in rat combined entorhinal cortex\u2010hippocampal slices by perfusion with low\u2010Mg<jats:sup>2+<\/jats:sup>\u2010artificial cerebrospinal fluid (ACSF). The antiepileptic properties of retigabine were evaluated as effect on the frequency and amplitude of the epileptiform activities as well as time of onset of the effect in the entorhinal cortex (EC) and in hippocampal area CA1 (CA1) by using extracellular recording techniques.<\/jats:p><jats:p> <jats:italic>Results<\/jats:italic>: Retigabine (20 \u03bc<jats:italic>M<\/jats:italic>) reversibly suppressed the recurrent short discharges otherwise sensitive only to high doses of valproate (VPA) but insensitive to standard antiepileptic drugs (AEDs) in CA1, whereas 10 \u03bc<jats:italic>M<\/jats:italic> reduced the frequency of discharges by 34 \u00b1 18.8%, with no significant effect on the amplitude. In EC, retigabine (50 \u03bc<jats:italic>M<\/jats:italic>) reversibly suppressed the seizure\u2010like events, whereas \u03bc<jats:italic>M<\/jats:italic> blocked seizure\u2010like events in 71.5% of the slices. The seizure\u2010like events were also sensitive to standard AEDs. Late recurrent discharges in EC that are not blocked by standard AEDs were reversibly suppressed by retigabine (100 \u03bc<jats:italic>M<\/jats:italic>), whereas 50 \u03bc<jats:italic>M<\/jats:italic> reduced the frequency of the discharges by 94.4 \u00b1 7.7%, and 20 \u03bc<jats:italic>M<\/jats:italic>, by 74.2 \u00b1 18.0%, with no significant effect on the amplitude.<\/jats:p><jats:p> <jats:italic>Conclusions<\/jats:italic>: Retigabine is an effective AED with suppressive effects on recurrent short discharges and on late recurrent discharges normally insensitive to standard AEDs.<\/jats:p>","DOI":"10.1111\/j.1528-1157.2000.tb01501.x","type":"journal-article","created":{"date-parts":[[2005,8,3]],"date-time":"2005-08-03T06:42:25Z","timestamp":1123051345000},"page":"28-33","source":"Crossref","is-referenced-by-count":52,"title":["Effects of Retigabine (D\u201023129) on Different Patterns of Epileptiform Activity Induced by Low Magnesium in Rat Entorhinal Cortex Hippocampal Slices"],"prefix":"10.1111","volume":"41","author":[{"given":"V.","family":"Armand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rundfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,2]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.1996.tb00304.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00101-8"},{"key":"e_1_2_1_4_2","first-page":"1641","article-title":"The phenyl carbamic acid ester D\u201023129 is highly effective in epilepsy models for generalized and focal seizures at nontoxic doses","volume":"20","author":"Tober C","year":"1994","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00073-8"},{"issue":"7","key":"e_1_2_1_6_2","first-page":"212","article-title":"The phenylcarbamic acid ester D\u201023129 is highly effective against amygdala kindled seizures in rats","author":"Tober C","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)11783-S"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(94)00077-A"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00050-X"},{"key":"e_1_2_1_10_2","first-page":"R160","article-title":"Multiple actions of the new anticonvulsant D\u201023129 on voltage\u2010gated inward currents and GABA\u2010induced currents in cultured neuronal cells","volume":"351","author":"Rundfeldt C","year":"1995","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"e_1_2_1_11_2","first-page":"203","article-title":"Potassium channel opening properties of D\u201023129 an anticonvulsant with potent effects in rodents models for generalized and focal seizures","volume":"21","author":"Rundfeldt C","year":"1995","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01249-1"},{"key":"e_1_2_1_13_2","first-page":"R2117","article-title":"The effects of D\u201023129 (ADD 230001) and standard anticonvulsant on the pair\u2010pulse paradigm in rat hippocampus in vitro","volume":"21","author":"Yonekawa WD","year":"1995","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1988.59.5.1476"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)91274-6"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1987.57.3.869"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(86)90595-1"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(87)90304-1"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(90)90757-Z"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(91)90090-3"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00169016"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(94)00067-7"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00175474"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-3806(95)00069-P"},{"key":"e_1_2_1_25_2","first-page":"17","article-title":"Anticonvulsive properties of ketamine and 2\u2010aminophosphonovalerate in the low magnesium epilepsy in rat hippocampal slices","volume":"1","author":"K\u00f6hr G","year":"1987","journal-title":"Neurosci Res Commun"},{"key":"e_1_2_1_26_2","first-page":"R10","article-title":"Low Mg2+ induced epileptiform activity in rat temporal cortex slices: development of pharmacoresistant epileptiform activity","volume":"418","author":"Zhang CL","year":"1991","journal-title":"Eur J Physiol"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199223040-00003"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1996.tb00037.x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(93)90049-D"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(85)90473-2"},{"key":"e_1_2_1_31_2","first-page":"17","article-title":"Anticonvulsive properties of ketamine and 2\u2010aminophosphonovalerate in the low magnesium epilepsy in rat hippocampal slices","volume":"1","author":"K\u00f6hr G","year":"1987","journal-title":"Neurosci Res Commun"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1993.69.6.2150"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00043.x"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1997.sp021842"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/376174a0"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199009000-00008"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)00258-9"},{"key":"e_1_2_1_38_2","first-page":"223","article-title":"Antiepileptic drugs: pharmacological mechanism and clinical efficacy with consideration of promising developmental stage compounds","volume":"42","author":"Rogawski MA","year":"1990","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.51.6.1077"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1157.2000.tb01501.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1157.2000.tb01501.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T07:34:06Z","timestamp":1698564846000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1157.2000.tb01501.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1111\/j.1528-1157.2000.tb01501.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1157.2000.tb01501.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}